medigraphic.com

2023, Número 3

<< Anterior Siguiente >>

Rev Hematol Mex 2023; 24 (3)


L-asparaginasa en el tratamiento de la leucemia linfoblástica aguda, sus efectos adversos y oportunidades en la optimización del tratamiento

Gándara MJA, Lares AI, Reyes EEA, Córdova HLP, Reyes GFM, Sandoval CA, Loera CV, Díaz GC, García VA, Nava RAR, Patrón RL, Almanza RH

Idioma: Español
Referencias bibliográficas: 97
Paginas: 145-162
Archivo PDF: 713.69 Kb.


RESUMEN

tratamiento contra la leucemia linfoblástica aguda ha mejorado a través de los años debido al desarrollo de estrategias de tratamiento cada vez más efectivas. La Lasparaginasa (L-Asp) es uno de los principales fármacos prescritos en el tratamiento de la leucemia linfoblástica aguda cuyo objetivo terapéutico es agotar sistemáticamente el aminoácido no esencial asparagina (Asp) y así causar la muerte de las células leucémicas; sin embargo, las reacciones de hipersensibilidad y la pancreatitis son los principales efectos adversos asociados con este medicamento. Se realizó una revisión de la bibliografía con base en la metodología Preferred Reporting Items for Systematic Reviews and Meta-Analyses en las bases de datos SCOPUS, Redalyc, SciELO, Science- Direct, PubMed y BVS Medline, con el objetivo de describir los avances de L-Asp en el tratamiento de la leucemia linfoblástica aguda, sus efectos adversos y oportunidades en la optimización del tratamiento. En primera instancia se obtuvieron 607 artículos que tocaban aspectos de la L-Asp, se realizó una selección de 97 artículos que aportaban respuestas a nuestros objetivos. De acuerdo con esta revisión, la capacidad de individualizar la terapia, ajustar la dosis o cambiar la formulación de L-Asp puede ayudar a reducir los efectos adversos, así como a identificar a los pacientes con inactivación silenciosa y de esta manera mejorar la seguridad y eficacia en pacientes pediátricos con leucemia linfoblástica aguda en tratamiento con L-Asp.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Whiteley AE, Price TT, Cantelli G, Sipkins DA. Leukaemia:a model metastatic disease. Nat Rev Cancer 2021; 21 (7):461-475. doi: 10.1038/s41568-021-00355-z. doi: 10.1038/s41568-021-00355-z.

  2. Leukaemia. (s/f). Worldhealthorganization.int. Recuperadoel 7 de junio de 2023, de https://platform.who.int/mortality/themes/theme-details/topics/indicator-groups/indicator-group-details/MDB/leukaemia.

  3. De Morais SB, De Souza TACB. Human L‑asparaginase:Acquiring knowledge of its activation (Review). Int J Oncol2021; 58 (4): 11. doi: 10.3892/ijo.2021.5191.

  4. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblasticleukemia. Pediatr Clin North Am 2015; 62 (1):61-73. doi:10.1016/j.pcl.2014.09.006.

  5. Kaushik M, Sinha P, Jaiswal P, Mahendru S, Roy K, KukretiS. Protein engineering and de novo designing of a biocatalyst.J Mol Recognit 2016; 29 (10): 499-503. https://doi.org/10.1002/jmr.2546.

  6. Viola RE. The ammonia-lyases: enzymes that use a widerange of approaches to catalyze the same type of reaction.Crit Rev Biochem Mol Biol 2019; 54 (6): 467-483. https://doi.org/10.1080/10409238.2019.1708261.

  7. Dingermann T. Recombinant therapeutic proteins: productionplatforms and challenges. Biotechnol J 2008; 3 (1):90-97. doi: 10.1002/biot.200700214.

  8. Avramis VI, Tiwari PN. Asparaginase (native ASNase orpegylated ASNase) in the treatment of acute lymphoblasticleukemia. Int J Nanomedicine 2006; 1 (3): 241-54.

  9. Cecconello DK, Magalhães MR, Werlang ICR, Lee MLM,Michalowski MB, Daudt LE. Asparaginase: an old drug withnew questions. Hematol Transfus Cell Ther 2020; 42 (3):275-282. doi: 10.1016/j.htct.2019.07.010.

  10. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, BaruchelA, et al. L-asparaginase treatment in acute lymphoblasticleukemia: a focus on Erwinia asparaginase. Cancer 2012;

  11. 117 (2): 238-49. doi: 10.1002/cncr.25489.11. Lang S, Uber. Desamidierung im Tierkorper. Beitraege zurChemischen Physiologie und Pathologie 1904; 190: 5321-345.

  12. Clementi A. La desemidation enzymatique de L-asparaginasechez les differentes especes animales et la significationphysiologique de sa presence dans l organiasma. Arch IntPhysiol 1922;19: 369-376.

  13. Kidd JG. Regression of transplanted lymphomas inducedin vivo by means of normal guinea pigserum. I. course oftransplanted cancers of various kinds in mice and rats givenguinea pig serum, horse serum or rabbit serum. J Exp Med1953; 98: 565-582. doi: 10.1084/jem.98.6.565.

  14. Broome JD. Factors which may influence the effectivenessof L-asparaginases as tumor inhibitors. Br J Canc 1961; 22:595-602. doi: 10.1038/bjc.1968.71.

  15. Broome JD. Antilymphoma activity of L-asparaginase invivo: clearance rates of enzyme preparations from guineapig serum and yeast in relation to their effect on tumorgrowth. J Natl Cancer Inst 1965; 35: 967-974.

  16. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW.L-asparaginase therapy for leukemia and other malignantneoplasms. Remission in human leukemia. JAMA 1967;202 (9): 882-888.

  17. Oettgen HF, Stephenson PA, Schwartz MK, LeeperRD, Tallai L, Tan CC, et al. Toxicity of E. coli L‑asparaginasein man. Cancer 1970; 25 (2): 253‑278.doi: 10.1002/1097-0142(197002)25:2<253::aidcncr2820250204>3.0.co;2-u.

  18. Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP. Developmentof asparaginase Erwinia chrysanthemi for thetreatment of acute lymphoblastic leukemia. Ann N Y AcadSci 2014; 1329: 81‑92. doi: 10.1111/nyas.12496.

  19. van der Sluis IM, Vrooman LM, Pieters R, Baruchel A, EscherichG, Goulden N, et al. Consensus expert recommendationsfor identification and management of asparaginase hypersensitivityand silent inactivation. Haematologica 2016; 101(3): 279-85. doi: 10.3324/haematol.2015.137380.

  20. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS,Avramis IA, Sather H, et al. Asparaginase antibody andasparaginase Aactivity in children with higher-risk acutelymphoblastic leukemia: Children’s Cancer Group StudyCCG-1961. J Pediatr Hematol Oncol 2004; 26 (4): 217-26.

  21. Burke MJ. How to manage asparaginase hypersensitivityin acute lymphoblastic leukemia. Future Oncol 2014; 10(16): 2615-27. doi: 10.2217/fon.14.138.

  22. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC,Rivera GK, et al. Hypersensitivity or development ofantibodies to asparaginase does not impact treatmentoutcome of childhood acute lymphoblastic leukemia.J Clin Oncol 2000; 18 (7): 1525-32. doi: 10.1200/JCO.2000.18.7.1525.

  23. Beckett A, Gervais D. What makes a good new therapeuticL-asparaginase? World J Microbiol Biotechnol 2019; 35(10): 152. https://doi.org/10.1007/s11274-019-2731-9.

  24. Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NL, Carol H,Lock RB. Pharmacokinetic modelling of an induction regimenfor in vivo combined testing of novel drugs against pediatricacute lymphoblastic leukemia xenografts. PloS One 2012; 7(3): e33894-e33994. doi: 10.1371/journal.pone.0033894.

  25. Pokrovskaya MV, Pokrovsky VS, Aleksandrova SS, SokolovNN, Zhdanov DD. Molecular analysis of L-asparaginases forclarification of the mechanism of action and optimizationof pharmacological functions. Pharmaceutics 2022; 14 (3):599. doi: 10.3390/pharmaceutics14030599.

  26. Nomme J, Su Y, Konrad M, Lavie A. Structures of apoand product-bound human L-asparaginase: insights intothe mechanism of autoproteolysis and substrate hydrolysis.Biochem 2012; 51 (34): 6816-6826. doi: 10.1021/bi300870g.

  27. Lubkowski J, Wlodawer A. Structural and biochemicalproperties of L-asparaginase. FEBS J 2021; 288 (14): 4183-4209. doi: 10.1111/febs.16042.

  28. Zhou R, Liang T, Li T, Huang J, Chen C. Possible mechanism ofmetabolic and drug resistance with L-asparaginase therapyin childhood leukaemia. Front Oncol 2023; 13:10700 69.doi: 10.3389/fonc.2023.1070069.

  29. Maese L, Rau RE. Current use of asparaginase in acutelymphoblastic leukemia/lymphoblastic lymphoma. FrontPediatr 2022; 10: 902117. doi: 10.3389/fped.2022.902117.

  30. Pagliardi GL, Gabutti V, Gavosto F. Mechanism of actionof L-asparaginase on the cell cycle and growth in acutelymphoblastic leukemia. Acta Haematol 1973; 50 (5): 257-268. https://doi.org/10.1159/000208358.

  31. Egler RA, Ahuja SP, Matloub Y. L-asparaginase in thetreatment of patients with acute lymphoblastic leukemia.J Pharmacol Pharmacother 2016; 7 (2): 62-71. doi:10.4103/0976-500X.184769.

  32. Sugimoto K, Suzuki HI, Fujimura T, Ono A, Kaga N, Isobe Y,et al. A clinically attainable dose of L-asparaginase targetsglutamine addiction in lymphoid cell lines. Cancer Sci 2015;106 (11): 1534-1543. doi: 10.1111/cas.12807.

  33. Heo YA, Syed YY, Keam SJ. Pegaspargase: A review in acutelymphoblastic leukaemia. Drugs 2019; 79 (7): 767-777. doi:10.1007/s40265-019-01120-1.

  34. Van Trimpont M, Peeters E, De Visser Y, Schalk AM, MondelaersV, De Moerloose B, et al. Novel insights on the use ofL-asparaginase as an efficient and safe anti-cancer therapy.Cancers 2022; 14 (4): 902. doi: 10.3390/cancers14040902.

  35. Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, CarrollAJ, Gastier-Foster JM, et al. Pharmacokinetic and pharmacodynamicproperties of calaspargase pegol Escherichiacoli L-asparaginase in the treatment of patients with acutelymphoblastic leukemia: results from Children's OncologyGroup Study AALL07P4. J Clin Oncol 2014; 32 (34): 3874-3882. doi: 10.1200/JCO.2014.55.5763.

  36. Brumano LP, da Silva FVS, Costa-Silva TA, Apolinário AC,Santos JHPM, Kleingesinds EK, et al. Development of L-asparaginasebiobetters: Current research status and reviewof the desirable quality profiles. Front Bioeng Biotechnol2019; 6: 212. https://doi.org/10.3389/fbioe.2018.00212.

  37. Maese L, Rizzari C, Coleman R, Power A, van der Sluis I,Rau RE. Can recombinant technology address asparaginaseErwinia chrysanthemi shortages?. Pediatr Blood Cancer2021; 68 (10): e29169. doi: 10.1002/pbc.29169.

  38. Bender C, Maese L, Carter-Febres M, Verma A. Clinicalutility of pegaspargase in children, adolescents and youngadult patients with acute lymphoblastic leukemia: A review.Blood Lymphat Cancer 2021; 11: 25-40. doi: 10.2147/BLCTT.S245210.

  39. Mondelaers V, Ferster A, Uyttebroeck A, Brichard B, vander Werff Ten Bosch J, Norga K, et al. Prospective, realtimemonitoring of pegylated Escherichia coli and Erwiniaasparaginase therapy in childhood acute lymphoblasticleukaemia and non-Hodgkin lymphoma in Belgium. Br JHaematol 2020; 190 (1): 105-114. doi: 10.1111/bjh.16495.

  40. Ramya LN, Doble M, Rekha VP, Pulicherla KK. L-Asparaginaseas potent anti-leukemic agent and its significanceof having reduced glutaminase side activity for bettertreatment of acute lymphoblastic leukaemia. Appl BiochemBiotechnol 2012; 167 (8): 2144-2159. doi: 10.1007/s12010-012-9755-z.

  41. Fernandez CA, Stewart E, Panetta JC, Wilkinson MR, MorrisonAR, Finkelman FD. Successful challenges using nativeE. coli asparaginase after hypersensitivity reactions to PEGylatedE. coli asparaginase. Cancer Chemother Pharmacol2014; 73 (6): 1307-1313. doi: 10.1007/s00280-014-2464-2.

  42. Haskell CM, Canellos GP, Leventhal BG, Carbone PP,Block JB, Serpick AA, et al. L-asparaginase: therapeuticand toxic effects in patients with neoplastic disease. NEngl J Med 1969; 281 (19): 1028-1034. doi: 10.1056/NEJM196911062811902.

  43. National Cancer Institute (NCI). Common TerminologyCriteria for Adverse Events v5.0 (CTCAE) 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

  44. Shinnick SE, Browning ML, Koontz SE. Managing hypersensitivityto asparaginase in pediatrics, adolescents, andyoung adults. J Pediatr Oncol Nurs 2013; 30 (2): 63-77. doi:10.1177/1043454212471728.

  45. Battistel AP, Rocha BSD, Santos MTD, Daudt LE, MichalowskiMB. Allergic reactions to asparaginase: retrospectivecohort study in pediatric patients with acute lymphoidleukemia. Hematol Transfus Cell Ther 2021; 43 (1): 9-14.doi: 10.1016/j.htct.2019.10.007.

  46. Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, MariniB. Asparaginase activity levels and monitoring in patientswith acute lymphoblastic leukemia. Leuk Lymphoma 2018;59 (8): 1797-1806. doi: 10.1080/10428194.2017.1386305.

  47. Tong WH, Pieters R, Kaspers GJ, te Loo DM, Bierings MB,van den Bos C, et al. A prospective study on drug monitoringof PEGasparaginase and Erwinia asparaginase andasparaginase antibodies in pediatric acute lymphoblasticleukemia. Blood 2014; 123: 2026-2033. doi: 10.1182/blood-2013-10-534347.

  48. Galindo-Rodríguez G, Jaime-Pérez JC, Salinas-CarmonaMC, González-Díaz SN, Castro-Corona Á, Cavazos-GonzálezR, et al. Do immunoglobulin G and immunoglobulin Eanti-l-asparaginase antibodies have distinct implicationsin children with acute lymphoblastic leukemia? A crosssectionalstudy. Rev Bras Hematol Hemoter 2017; 39 (3):202-209. doi: 10.1016/j.bjhh.2016.11.006.

  49. Siebel C, Lanvers-Kaminsky C, Alten J, Smisek P, Nath CE,Rizzari C, et al. Impact of antibodies against polyethyleneglycol on the pharmacokinetics of PEGylated asparaginasein children with acute lymphoblastic leukaemia: Apopulation pharmacokinetic approach. Eur J Drug MetabPharmacokinet 2022; 47 (2): 187-198. doi: 10.1007/s13318-021-00741-w.

  50. Yen HJ, Chang WH, Liu HC, Yeh TC, Hung GY, Wu KH, et al.Outcomes following discontinuation of E. coli L-asparaginaseupon severe allergic reactions in children with acutelymphoblastic leukemia. Pediatr Blood Cancer 2016; 63(4): 665-670. doi: 10.1002/pbc.25869.

  51. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, MeiselmanHJ, et al. Antibody against poly(ethylene glycol)adversely affects PEG-asparaginase therapy in acutelymphoblastic leukemia patients. Cancer 2007; 110 (1):103-111. doi: 10.1002/cncr.22739.

  52. Hunger S. COG Pharmacy Committee. Parental and oralchemotherapy administration guidelines used by theChildren’s Oncology Group (Version 6). In: Archives of theChildren’s Oncology Group; 2010.

  53. Ameen F, Alshehri WA, Al-Enazi NM, Almansob A. L-Asparaginaseactivity analysis, ansZ gene identification and anticanceractivity of a new Bacillus subtilis isolated from spongesof the Red Sea. Biosci Biotechnol Biochem 2020; 84(12): 2576-2584. doi: 10.1080/09168451.2020.1807310.

  54. Juluri KR, Siu C, Cassaday RD. Asparaginase in the treatmentof acute lymphoblastic leukemia in adults: current evidenceand place in therapy. Blood Lymphat Cancer 2022; 12: 55-79. doi: 10.2147/BLCTT.S342052.

  55. Bade NA, Lu C, Patzke CL, Baer M, et al. Optimizing pegylatedasparaginase use: An institutional guideline for dosing,monitoring, and management. J Oncol Pharm Pract 2020;26 (1): 74-92. doi: 10.1177/1078155219838316.

  56. Medawar CV, Mosegui GBG, Vianna CMM, Costa TMAD.PEG-asparaginase and native Escherichia coli L-asparaginasein acute lymphoblastic leukemia in children andadolescents: a systematic review. Hematol Transfus CellTher 2020; 42 (1): 54-61. doi: 10.1016/j.htct.2019.01.013.

  57. Vultaggio A, Perlato M, Nencini F, Vivarelli E, Maggi E,Matucci A. How to prevent and mitigate hypersensitivityreactions to biologicals induced by anti-drug antibodies?Front Immunol 2021; 12: 765747. doi: 10.3389/fimmu.2021.765747.

  58. Nguyen HA, Su Y, Zhang JY, Antanasijevic A, Caffrey M,Schalk AM, et al. A novel L-asparaginase with low lglutaminasecoactivity is highly efficacious against bothT- and B-cell acute lymphoblastic leukemias in vivo. CancerRes 2018; 78 (6): 1549-1560. doi: 10.1158/0008-5472.CAN-17-2106.

  59. Chan WK, Lorenzi PL, Anishkin A, Purwaha P, Rogers DM,Sukharev S, et al. The glutaminase activity of L-asparaginaseis not required for anticancer activity against ASNS-negativecells. Blood 2014; 123 (23): 3596-3606. doi: 10.1182/blood-2013-10-535112.

  60. Sharma A, Kaushik V, Goel M. Insights into the distributionand functional properties of l-asparaginase in the archaealdomain and characterization of Picrophilus torridus asparaginase belonging to the novel family Asp2like1. ACS Omega2022; 7 (45): 40750-40765. https://doi.org/10.1021/acsomega.2c01127.

  61. Papageorgiou AC, Posypanova GA, Andersson CS, SokolovNN, Krasotkina J. Structural and functional insights intoErwinia carotovora L-asparaginase. FEBS J 2008; 275 (17):4306-4316. doi: 10.1111/j.1742-4658.2008.06574.x.

  62. Krishna M, Nadler SG. Immunogenicity to biotherapeutics- The role of anti-drug immune complexes. Front Immunol2016; 7: 21. doi: 10.3389/fimmu.2016.00021.

  63. Chiu M, Tardito S, Pillozzi S, Arcangeli A, Armento A, UggeriJ, et al. Glutamine depletion by crisantaspase hinders thegrowth of human hepatocellular carcinoma xenografts. Br JCancer 2014; 111 (6): 1159-1167. https://doi.org/10.1038/bjc.2014.425.

  64. Parmentier JH, Maggi M, Tarasco E, Scotti C, AvramisVI, Mittelman SD. Glutaminase activity determinescytotoxicity of L-asparaginases on most leukemia celllines. Leuk Res 2015; 39 (7): 757-762. doi: 10.1016/j.leukres.2015.04.008.

  65. Yuan L, Sheng X, Willson AK, Roque DR, Stine JE, Guo H, etal. Glutamine promotes ovarian cancer cell proliferationthrough the mTOR/S6 pathway. Endocr Relat Cancer 2015;22 (4): 577-591. doi: 10.1530/ERC-15-0192.

  66. Zhao JS, Shi S, Qu HY, Keckesova Z, Cao ZJ, Yang LX, et al.Glutamine synthetase licenses APC/C-mediated mitoticprogression to drive cell growth. Nat Metab 2022; 4 (2):239-253. doi: 10.1038/s42255-021-00524-2.

  67. He S, Zhang S, Yao Y, Xu B, Niu Z, Liao F, et al. Turbulenceof glutamine metabolism in pan-cancer prognosis and immunemicroenvironment. Front Oncol 2022; 12: 1064127.doi: 10.3389/fonc.2022.1064127.

  68. DeBerardinis RJ, Cheng T. Q's next: the diverse functionsof glutamine in metabolism, cell biology and cancer. Oncogene2010; 29 (3): 313-324. doi: 10.1038/onc.2009.358.

  69. Nussbaum V, Lubcke N, Findlay R. Hyperammonemia secondaryto asparaginase: A case series. J Oncol Pharm Pract2016; 22 (1): 161-164. doi: 10.1177/1078155214551590.

  70. Durden DL, Salazar AM, Distasio JA. Kinetic analysis of hepatotoxicityassociated with antineoplastic asparaginases.Cancer Res 1983; 43 (4): 1602-1605.

  71. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, AvramisIA, Avramis VI. Changes of amino acid serum levels in pediatricpatients with higher-risk acute lymphoblastic leukemia(CCG-1961). In Vivo 2004; 18 (2): 107-112.

  72. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME,Forman EN. Effect of L-asparaginase administration oncoagulation and platelet function in children with leukemia.J Clin Oncol 1987; 5 (5): 811-817. doi: 10.1200/JCO.1987.5.5.811.

  73. Truelove E, Fielding AK, Hunt BJ. The coagulopathy andthrombotic risk associated with L-asparaginase treatmentin adults with acute lymphoblastic leukaemia. Leukemia2013; 27 (3): 553-559. doi: 10.1038/leu.2012.290.

  74. Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, MlynarskiW. The cross-reactivity of anti-asparaginase antibodiesagainst different l-asparaginase preparations. Clin Exp Med2009; 9 (2): 113-136. doi: 10.1007/s10238-008-0026-9.

  75. Douer D, Gökbuget N, Stock W, Boissel N. Optimizing useof L-asparaginase-based treatment of adults with acutelymphoblastic leukemia. Blood Rev 2022; 53: 100908. doi:10.1016/j.blre.2021.100908.

  76. Li RJ, Jin R, Liu C, Cao X, Manning ML, Di XM, et al. FDA ApprovalSummary: Calaspargase pegol-mknl for treatment ofacute lymphoblastic leukemia in children and young adults.Clin Cancer Res 2020; 26 (2): 328-331. doi: 10.1158/1078-0432.CCR-19-1255.

  77. Lin T, Hernandez-Illas M, Rey A, Jenkins J, Chandula R,Silverman JA, et al. A randomized phase i study to evaluatethe safety, tolerability, and pharmacokinetics ofrecombinant Erwinia asparaginase (JZP-458) in healthyadult volunteers. Clin Transl Sci 2021; 14 (3): 870-879. doi:10.1111/cts.12947.

  78. Lynggaard LS, Vaitkeviciene G, Langenskiöld C, LehmannAK, Lähteenmäki PM, Lepik K, et al. Asparaginase encapsulatedin erythrocytes as second-line treatment in hypersensitivepatients with acute lymphoblastic leukaemia. Br JHaematol 2022; 197 (6): 745-754. doi: 10.1111/bjh.18152.

  79. Aldoss I, Stein AS. Advances in adult acute lymphoblasticleukemia therapy. Leuk Lymphoma 2018; 59 (5): 1033-1050. doi: 10.1080/10428194.2017.1354372.

  80. National Comprehensive Cancer Network. NCCN ClinicalPractice Guidelines in Oncology (NCCN Guidelines®): acutelymphoblastic leukemia (ALL) version 2.2021- September9, 2021.

  81. Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA,van den Bos C, van der Sluis IM. Individualized asparaginasedosing in childhood acute lymphoblastic leukemia. J ClinOncol 2020; 38 (7): 715-724. doi: 10.1200/JCO.19.02292.

  82. Hijiya N, van der Sluis IM. Asparaginase-associatedtoxicity in children with acute lymphoblastic leukemia.Leuk Lymphoma 2016; 57 (4): 748-757. doi:10.3109/10428194.2015.1101098.

  83. Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG,Brown PA. Universal premedication and therapeutic drugmonitoring for asparaginase-based therapy preventsinfusion-associated acute adverse events and drug substitutions.Pediatr Blood Cancer 2019; 66 (8): e27797. doi:10.1002/pbc.27797.

  84. Sassen SD, Mathôt RA, Pieters R, Kloos R, et al. Populationpharmacokinetics of intravenous Erwinia asparaginasein pediatric acute lymphoblastic leukemia patients.Haematologica 2017; 102 (3): 552-561. doi: 10.3324/haematol.2016.149195.

  85. Würthwein G, Lanvers-Kaminsky C, Siebel C, Gerß J,Möricke A, Zimmermann M, et al. Population pharmacokineticsof PEGylated asparaginase in children with acutelymphoblastic leukemia: Treatment phase dependencyand predictivity in case of missing data. Eur J Drug Metab Pharmacokinet 2021; 46 (2): 289-300. doi: 10.1007/s13318-021-00670-8.

  86. Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, et al. Currenttrends in drug metabolism and pharmacokinetics. ActaPharm Sin B 2019; 9 (6): 1113-1144. doi: 10.1016/j.apsb.2019.10.001.

  87. Lin T, Dumas T, Kaullen J, Berry NS, Choi MR, Zomorodi K,et al. Population pharmacokinetic model development andsimulation for recombinant Erwinia asparaginase producedin Pseudomonas fluorescens (JZP-458). Clin Pharmacol DrugDev 2021; 10 (12): 1503-1513. doi: 10.1002/cpdd.1002.

  88. Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES,Wetzler M. Pharmacogenetics predictive of response andtoxicity in acute lymphoblastic leukemia therapy. BloodRev 2015; 29 (4): 243-249. doi: 10.1016/j.blre.2015.01.001.

  89. Liu C, Yang W, Devidas M, Cheng C, Pei D, Smith C, et al.Clinical and genetic risk factors for acute pancreatitis inpatients with acute lymphoblastic leukemia. J Clin Oncol2016; 34 (18): 2133-2140. doi: 10.1200/JCO.2015.64.5812.

  90. Plourde PV, Jeha S, Hijiya N, Keller FG, Silverman LB,Rheingold SR, et al. Safety profile of asparaginase Erwiniachrysanthemi in a large compassionate-use trial. PediatrBlood Cancer 2014; 61 (7): 1232-1238. doi: 10.1002/pbc.24938.

  91. Lanvers-Kaminsky C, Rüffer A, Würthwein G, Gerss J, ZucchettiM, Ballerini A, et al. Therapeutic drug monitoring ofasparaginase activity-method comparison of MAAT andAHA test used in the International AIEOP-BFM ALL 2009Trial. Ther Drug Monit 2018; 40 (1): 93-102. doi: 10.1097/FTD.0000000000000472.

  92. Avramis VI, Sencer S, Periclou AP, Sather H, BostromBC, Cohen LJ, et al. A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugatedasparaginase for treatment of children with newlydiagnosed standard-risk acute lymphoblastic leukemia: aChildren’s Cancer Group study. Blood 2002; 99 (6): 1986-1994. doi: 10.1182/blood.v99.6.1986.

  93. Vrooman LM, Stevenson KE, Supko JG, O’Brien J, DahlbergSE, Asselin BL, et al. Postinduction dexamethasone andindividualized dosing of Escherichia coli L-asparaginaseeach improve outcome of children and adolescents withnewly diagnosed acute lymphoblastic leukemia: Resultsfrom a randomized study—Dana-Farber Cancer Institute.J Clin Oncol 2013; 31 (9): 1202-10. doi: 10.1200/JCO.2012.43.2070.

  94. Gándara-Mireles JA, Lares-Asseff I, Reyes Espinoza EA,Loera Castañeda V, Grijalva Avila JC, Villanueva Fierro I,et al. Rapid asparagine depletion as a possible risk markerfor pancreatitis in children with acute lymphoblasticleukemia under treatment with L-asparaginase: casereport from five patients. Biomed J Sci Tech Res 2023;50 (4): 41929-41934.

  95. Erenler SO, Geckil H. Effect of vitreoscilla hemoglobin andculture conditions on production of bacterial L-asparaginase,an oncolytic enzyme. Appl Biochem Biotechnol 2014;173 (8): 2140-2151. doi: 10.1007/s12010-014-1016-x.

  96. Radadiya A, Zhu W, Coricello A, Alcaro S, Richards NGJ.Improving the treatment of acute lymphoblastic leukemia.Biochemistry 2020; 59 (35): 3193-3200. doi: 10.1021/acs.biochem.0c00354.

  97. Wang N, Ji W, Wang L, Wu W, Zhang W, Wu Q, et al. Overviewof the structure, side effects, and activity assays ofl-asparaginase as a therapy drug of acute lymphoblasticleukemia. RSC Med Chem 2022; 13 (2): 117-128.




2020     |     www.medigraphic.com